-
1
-
-
77952877804
-
Molecular genetics and phenomics of ret mutations: Impact on prognosis of mtc
-
Frank-Raue K, Rondot S, Raue F. Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC. Mol Cell Endocrinol. 2010;322:2-7.
-
(2010)
Mol Cell Endocrinol.
, vol.322
, pp. 2-7
-
-
Frank-Raue, K.1
Rondot, S.2
Raue, F.3
-
2
-
-
77954219743
-
Targeted therapy of thyroid cancer
-
Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharmacol. 2010;80:592-601.
-
(2010)
Biochem Pharmacol.
, vol.80
, pp. 592-601
-
-
Sherman, S.I.1
-
3
-
-
84655175698
-
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase iii trial
-
Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30: 134-141.
-
(2012)
J Clin Oncol.
, vol.30
, pp. 134-141
-
-
Wells Jr., S.A.1
Robinson, B.G.2
Gagel, R.F.3
-
4
-
-
84863890768
-
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: Us food and drug administration drug approval summary
-
Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: US Food and Drug Administration drug approval summary. Clin Cancer Res. 2012;18:3722-3730.
-
(2012)
Clin Cancer Res.
, vol.18
, pp. 3722-3730
-
-
Thornton, K.1
Kim, G.2
Maher, V.E.3
-
5
-
-
84873883043
-
Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer
-
Hart CD, De Boer RH. Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer. Onco Targets Ther. 2013;6:1-7.
-
(2013)
Onco Targets Ther.
, vol.6
, pp. 1-7
-
-
Hart, C.D.1
De Boer, R.H.2
-
6
-
-
73149115248
-
Targeting the ret pathway in thyroid cancer
-
Wells SA Jr, Santoro M. Targeting the RET pathway in thyroid cancer. Clin Cancer Res. 2009;15:7119-7123.
-
(2009)
Clin Cancer Res.
, vol.15
, pp. 7119-7123
-
-
Wells Jr., S.A.1
Santoro, M.2
-
9
-
-
84875143449
-
Ret inhibition: Implications in cancer therapy
-
Borrello MG, Ardini E, Locati LD, Greco A, Licitra L, Pierotti MA. RET inhibition: implications in cancer therapy. Expert Opin Ther Targets. 2013;17:403-419.
-
(2013)
Expert Opin Ther Targets.
, vol.17
, pp. 403-419
-
-
Borrello, M.G.1
Ardini, E.2
Locati, L.D.3
Greco, A.4
Licitra, L.5
Pierotti, M.A.6
-
11
-
-
33745939304
-
Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by ret inhibitor rpi-1
-
Petrangolini G, Cuccuru G, Lanzi C, et al. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1. Biochem Pharmacol. 2006;72:405-414.
-
(2006)
Biochem Pharmacol.
, vol.72
, pp. 405-414
-
-
Petrangolini, G.1
Cuccuru, G.2
Lanzi, C.3
-
12
-
-
77956114179
-
Combination of ret sirna and irinotecan inhibited the growth of medullary thyroid carcinoma tt cells and xenografts via apoptosis
-
Koga K, Hattori Y, Komori M, et al. Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis. Cancer Sci. 2010;101:941-947.
-
(2010)
Cancer Sci.
, vol.101
, pp. 941-947
-
-
Koga, K.1
Hattori, Y.2
Komori, M.3
-
13
-
-
79953783589
-
Evaluation of systemic targeting of ret oncogene-basedmtcwith tumor-selective peptide-Tagged ad vectors in clinical mouse models
-
Schmidt A, Eipel C, Fürst K, Sommer N, Pahnke J, Pützer BM. Evaluation of systemic targeting of RET oncogene-basedMTCwith tumor-selective peptide-Tagged Ad vectors in clinical mouse models. Gene Ther. 2011;18:418-423.
-
(2011)
Gene Ther.
, vol.18
, pp. 418-423
-
-
Schmidt, A.1
Eipel, C.2
Fürst, K.3
Sommer, N.4
Pahnke, J.5
Pützer, B.M.6
-
14
-
-
1442295841
-
Apoptosis and dependence receptors: A molecular basis for cellular addiction
-
Bredesen DE, Mehlen P, Rabizadeh S. Apoptosis and dependence receptors: a molecular basis for cellular addiction. Physiol Rev. 2004;84:411-430.
-
(2004)
Physiol Rev.
, vol.84
, pp. 411-430
-
-
Bredesen, D.E.1
Mehlen, P.2
Rabizadeh, S.3
-
15
-
-
33746961739
-
Mechanisms of disease: Oncogene addiction-A rationale for molecular targeting in cancer therapy
-
Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction-A rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol. 2006;3:448-457.
-
(2006)
Nat Clin Pract Oncol.
, vol.3
, pp. 448-457
-
-
Weinstein, I.B.1
Joe, A.K.2
-
16
-
-
37249003928
-
Oncogene addiction: Setting the stage for molecularly targeted cancer therapy
-
Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007;21:3214-3231.
-
(2007)
Genes Dev.
, vol.21
, pp. 3214-3231
-
-
Sharma, S.V.1
Settleman, J.2
-
17
-
-
4344566311
-
Role of men2a-derived ret in maintenance and proliferation of medullary thyroid carcinoma
-
Drosten M, Hilken G, Böckmann M, et al. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. J Natl Cancer Inst. 2004;96:1231-1239.
-
(2004)
J Natl Cancer Inst.
, vol.96
, pp. 1231-1239
-
-
Drosten, M.1
Hilken, G.2
Böckmann, M.3
-
18
-
-
80051783194
-
Interplay between ret and fap-1 regulates cd95-mediated apoptosis in medullary thyroid cancer cells
-
Nicolini V, Cassinelli G, Cuccuru G, et al. Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells. Biochem Pharmacol. 2011;82:778-788.
-
(2011)
Biochem Pharmacol.
, vol.82
, pp. 778-788
-
-
Nicolini, V.1
Cassinelli, G.2
Cuccuru, G.3
-
19
-
-
78049462514
-
Phase ii study of daily sunitinib in fdg-pet-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation
-
Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16:5260-5268.
-
(2010)
Clin Cancer Res.
, vol.16
, pp. 5260-5268
-
-
Carr, L.L.1
Mankoff, D.A.2
Goulart, B.H.3
-
20
-
-
33846034015
-
Biochemical mechanisms of cisplatin cytotoxicity
-
Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem. 2007;7:3-18.
-
(2007)
Anticancer Agents Med Chem.
, vol.7
, pp. 3-18
-
-
Cepeda, V.1
Fuertes, M.A.2
Castilla, J.3
Alonso, C.4
Quevedo, C.5
Pérez, J.M.6
-
21
-
-
0038494539
-
Loss of druginduced activation of the cd95 apoptotic pathway in a cisplatinresistant testicular germ cell tumor cell line
-
Spierings DC, de Vries EG, Vellenga E, de Jong S. Loss of druginduced activation of the CD95 apoptotic pathway in a cisplatinresistant testicular germ cell tumor cell line. Cell Death Differ. 2003; 10:808-822.
-
(2003)
Cell Death Differ.
, vol.10
, pp. 808-822
-
-
Spierings, D.C.1
De Vries, E.G.2
Vellenga, E.3
De Jong, S.4
-
22
-
-
2442693091
-
Cisplatin-induced cd95 redistribution into membrane lipid rafts of ht29 human colon cancer cells
-
Lacour S, Hammann A, Grazide S, et al. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res. 2004;64:3593-3598.
-
(2004)
Cancer Res.
, vol.64
, pp. 3593-3598
-
-
Lacour, S.1
Hammann, A.2
Grazide, S.3
-
23
-
-
84865576732
-
Subcellular targets of cisplatin cytotoxicity: An integrated view
-
Sancho-Martínez SM, Prieto-García L, Prieto M, López-Novoa JM, López-Hernández FJ. Subcellular targets of cisplatin cytotoxicity: an integrated view. Pharmacol Ther. 2012;136:35-55.
-
(2012)
Pharmacol Ther.
, vol.136
, pp. 35-55
-
-
Sancho-Martínez, S.M.1
Prieto-García, L.2
Prieto, M.3
López-Novoa, J.M.4
López-Hernández, F.J.5
-
24
-
-
12244301581
-
In vivo antitumor activity of su11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
-
Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327-337.
-
(2003)
Clin Cancer Res.
, vol.9
, pp. 327-337
-
-
Mendel, D.B.1
Laird, A.D.2
Xin, X.3
-
25
-
-
0033883775
-
Thyroid carcinoma cells are resistant to fas-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand
-
Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2000;60:4122-4129.
-
(2000)
Cancer Res.
, vol.60
, pp. 4122-4129
-
-
Mitsiades, N.1
Poulaki, V.2
Tseleni-Balafouta, S.3
Koutras, D.A.4
Stamenkovic, I.5
-
26
-
-
58149086851
-
Synthesis, modeling, and ret protein kinase inhibitory activity of 3-And 4-substituted -carbolin-1-ones
-
Cincinelli R, Cassinelli G, Dallavalle S, et al. Synthesis, modeling, and RET protein kinase inhibitory activity of 3-And 4-substituted -carbolin-1-ones. J Med Chem. 2008;51:7777-7787.
-
(2008)
J Med Chem.
, vol.51
, pp. 7777-7787
-
-
Cincinelli, R.1
Cassinelli, G.2
Dallavalle, S.3
-
27
-
-
33947504730
-
Sunitinib: From rational design to clinical efficacy
-
Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25:884-896.
-
(2007)
J Clin Oncol.
, vol.25
, pp. 884-896
-
-
Chow, L.Q.1
Eckhardt, S.G.2
-
28
-
-
79960094269
-
Mammalian target of rapamycin pathway activation is associated to ret mutation status in medullary thyroid carcinoma
-
Rapa I, Saggiorato E, Giachino D, et al. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. J Clin Endocrinol Metab. 2011;96: 2146-2153.
-
(2011)
J Clin Endocrinol Metab.
, vol.96
, pp. 2146-2153
-
-
Rapa, I.1
Saggiorato, E.2
Giachino, D.3
-
29
-
-
76549129820
-
Drug combination studies and their synergy quantification using the chou-Talalay method
-
Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440-446.
-
(2010)
Cancer Res.
, vol.70
, pp. 440-446
-
-
Chou, T.C.1
-
30
-
-
84857366779
-
The autophagic paradox in cancer therapy
-
Wu WK, Coffelt SB, Cho CH, et al. The autophagic paradox in cancer therapy. Oncogene. 2012;31:939-953.
-
(2012)
Oncogene.
, vol.31
, pp. 939-953
-
-
Wu, W.K.1
Coffelt, S.B.2
Cho, C.H.3
-
31
-
-
84862295360
-
Guidelines for the use and interpretation of assays for monitoring autophagy
-
Klionsky DJ, Abdalla FC, Abeliovich H, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;8:445-544.
-
(2012)
Autophagy.
, vol.8
, pp. 445-544
-
-
Klionsky, D.J.1
Abdalla, F.C.2
Abeliovich, H.3
-
32
-
-
79952122944
-
Cell death assays for drug discovery
-
Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov. 2011;10:221-237.
-
(2011)
Nat Rev Drug Discov.
, vol.10
, pp. 221-237
-
-
Kepp, O.1
Galluzzi, L.2
Lipinski, M.3
Yuan, J.4
Kroemer, G.5
-
33
-
-
82555189379
-
Lysosomal sequestration of sunitinib: A novel mechanism of drug resistance
-
Gotink KJ, Broxterman HJ, Labots M, et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res. 2011;17:7337-7346.
-
(2011)
Clin Cancer Res.
, vol.17
, pp. 7337-7346
-
-
Gotink, K.J.1
Broxterman, H.J.2
Labots, M.3
-
34
-
-
69249140641
-
Lysosomes as "suicide bags" in cell death: Myth or reality?
-
Turk B, Turk V. Lysosomes as "suicide bags" in cell death: myth or reality? J Biol Chem. 2009;284:21783-21787.
-
(2009)
J Biol Chem.
, vol.284
, pp. 21783-21787
-
-
Turk, B.1
Turk, V.2
-
35
-
-
84878347807
-
Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer
-
Paul I, Chacko AD, Stasik I, et al. Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer. Cell Death Dis. 2012;3:e449.
-
(2012)
Cell Death Dis.
, vol.3
-
-
Paul, I.1
Chacko, A.D.2
Stasik, I.3
-
36
-
-
79953328085
-
Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models
-
Broutin S, Ameur N, Lacroix L, et al. Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models. Clin Cancer Res. 2011;17: 2044-2054.
-
(2011)
Clin Cancer Res.
, vol.17
, pp. 2044-2054
-
-
Broutin, S.1
Ameur, N.2
Lacroix, L.3
-
37
-
-
84869460494
-
Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer
-
Lin CI, Whang EE, Lorch JH, Ruan DT. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer. Surgery. 2012;152:1142-1149.
-
(2012)
Surgery.
, vol.152
, pp. 1142-1149
-
-
Lin, C.I.1
Whang, E.E.2
Lorch, J.H.3
Ruan, D.T.4
-
39
-
-
84861671713
-
Lysosomal pathways to cell death and their therapeutic applications
-
Česen MH, Pegan K, Spes A, Turk B. Lysosomal pathways to cell death and their therapeutic applications. Exp Cell Res. 2012;318: 1245-1251.
-
(2012)
Exp Cell Res.
, vol.318
, pp. 1245-1251
-
-
Česen, M.H.1
Pegan, K.2
Spes, A.3
Turk, B.4
-
40
-
-
84863906261
-
Kinase inhibitors for advanced medullary thyroid carcinoma
-
Schlumberger M, Massicotte MH, Nascimento CL, Chougnet C, Baudin E, Leboulleux S. Kinase inhibitors for advanced medullary thyroid carcinoma. Clinics. 2012;67:125-129.
-
(2012)
Clinics.
, vol.67
, pp. 125-129
-
-
Schlumberger, M.1
Massicotte, M.H.2
Nascimento, C.L.3
Chougnet, C.4
Baudin, E.5
Leboulleux, S.6
|